Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health, Inc. director and CEO Charles DiVita III reported a mix of stock sales, grants, and conversions. He sold 50,145 shares of common stock at $5.117 per share in an open-market transaction, with a footnote stating the sale was to cover tax withholding obligations from vesting equity awards. After this sale, he directly held 327,862 common shares.
DiVita also acquired 692,041 restricted stock units and 23,591 performance stock units, each representing a contingent right to receive one share of Teladoc common stock on a one-for-one basis, subject to vesting schedules tied in part to 2025 financial metrics. Additional exercises and conversions of 169,107 and 7,864 derivative units into common shares were reported, reflecting ongoing equity-based compensation activity.
Teladoc Health, Inc.’s Chief Accounting Officer, Joseph Ronald Catapano, reported a mix of stock sales, vesting, and new equity awards. He sold 1,333 shares of common stock at $5.117 per share, with a footnote stating the sale was made to cover tax withholding tied to vesting of his restricted and performance stock units.
On the equity award side, he received a grant of 15,000 restricted stock units, each representing a contingent right to one share of Teladoc common stock, and 465 performance stock units earned based on 2025 financial metrics, also convertible one-for-one into common shares. Footnotes state these awards generally vest one-third on the first anniversary of the grant or earning date, with the remainder vesting in eight substantially equal quarterly installments thereafter. Following these transactions, he directly owned 8,841 shares of common stock, plus outstanding RSU and PSU awards.
Teladoc Health, Inc. executive Kelly Bliss, President of U.S. Group Health, reported a mix of stock sales and equity awards. Bliss sold 26,647 shares of common stock in an open-market transaction at $5.117 per share to cover tax withholding obligations related to vesting equity awards, and held 84,747 common shares afterward.
On March 1, 2026, Bliss received a grant of 181,661 restricted stock units, each representing a contingent right to one Teladoc share, generally vesting one-third on the first anniversary of the grant date with the balance in eight quarterly installments. Around February 27, 2026, multiple restricted stock unit and performance stock unit awards were exercised or earned, including 27,458 performance stock units determined using metrics tied to Teladoc’s 2025 financial results, all converting to common stock on a one-for-one basis.
Fernando Madeira Rodrigues reported a proposed sale of 25,086 common shares tied to restricted stock vesting on 03/01/2026. The filing lists the shares as to be sold through Fidelity Brokerage Services LLC on the NYSE.
It also discloses prior sales in the past three months: 4,209 shares sold on 12/03/2025 for $31,483.32 and 16,314 shares sold on 03/02/2026 for $83,473.84.
Teladoc Health executive Carlos Nueno reported multiple equity transactions involving Teladoc Health, Inc. common stock and equity awards. On March 2, 2026, he sold 20,165 shares of common stock in an open‑market transaction at $5.117 per share, with a footnote stating the sale was to cover tax withholding obligations from vesting awards.
On March 1, 2026, he received a grant of 173,010 restricted stock units with each unit representing a contingent right to one Teladoc share. On February 27, 2026, several blocks of restricted stock units and performance stock units converted into common stock on a one‑for‑one basis, increasing his shareholdings. After these transactions, he directly owned 50,595 common shares.
Teladoc Health, Inc. executive Fernando M. Rodrigues, President of BetterHelp, reported multiple stock transactions involving common shares and restricted stock units. He sold 16,314 common shares at $5.117 per share and 25,086 shares at $4.982 per share, totaling 41,400 shares sold.
Footnotes state these shares were sold to cover tax withholding obligations tied to vesting of restricted stock units and were executed under a Rule 10b5-1 trading plan adopted on November 3, 2025. Rodrigues also reported grants and exercises of restricted stock units, including 181,661 units granted on March 1, 2026, which each represent a contingent right to receive one share of Teladoc common stock and vest over time in scheduled installments.
Filer submitted a Form 144 reporting proposed sales of common stock related to compensation vesting. The filing lists 16,314 shares under "Securities To Be Sold" with a date of 02/27/2026. It also records prior sales: 2,324 shares on 12/02/2025 and 4,209 shares on 12/03/2025.
The broker address shown is Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI. The excerpt includes an NYSE listing and a numeric reference 178,396,434 alongside 03/02/2026.
Teladoc Health (TDOC) insider sale notice: a proposal to sell 50,145 common shares tied to restricted stock vesting on 02/27/2026 as compensation. The filing also records a prior sale of 17,138 common shares on 12/11/2025 by Charles Divita for $130,836.63.
TDOC submitted a Form 144 notice reporting 26,647 shares of Common stock associated with a restricted stock vesting event on 02/27/2026; the filing lists Fidelity Brokerage Services LLC as the selling broker and the exchange as NYSE. The filing notes a prior sale by Kelly Bliss of 4,582 shares on 12/02/2025 for $34,311.39.
Tdoc, Inc. filed a Form 144 disclosing a proposed sale of 27,083 common shares. The securities are described as Restricted Stock Vesting with a vesting/transaction date of 02/27/2026 and are listed as issuer/compensation-related.
The filing also reports prior sales of 5,720 common shares on 12/02/2025 by Adam Vandervoort. The notice names Fidelity Brokerage Services LLC as the broker and is tied to NYSE-listed common stock.